STOCK COMPARISON
Tapdi Oksijen AS vs HCA Healthcare: Fair Value & Quality
Both stocks run through our 21 valuation models. Here is how Tapdi Oksijen AS (TNZTP) and HCA Healthcare (HCA) compare, as of Aug 2, 2026.
As of Aug 2, 2026, Fair Value Calculator sees HCA Healthcare as the more attractively valued of the two: Tapdi Oksijen AS trades at TRY 28.32 versus a fair value of TRY 22.82 (-19%), while HCA Healthcare trades at $403 versus $555 (+38%).
Tapdi Oksijen AS
TNZTP.IS · TRY · Energy
-19%
above fair value
overvalued
PriceTRY 28.32
Fair ValueTRY 22.82
Quality54/100
HCA Healthcare
HCA · USD · Health Care
+38%
upside to fair value
undervalued
Price$403
Fair Value$555
Quality62/100
Head-to-head numbers
Green value = the better side for that row (for valuation multiples: lower = cheaper).
Tapdi Oksijen ASHCA Healthcare
Valuation
16.7×P/E (TTM)12.5×
3.28×P/S (TTM)1.06×
1.41×P/B—
8.3×EV/EBITDA7.8×
—PEG1.18×
—Dividend yield0.8%
—Dividend per share$2.94
Profitability
20%Net margin9%
28%Operating margin15%
9%Return on equity136%
7%Return on assets12%
Growth
3%Revenue growth (YoY)4%
47.2%Avg. growth/yr (3Y)7.9%
76.2%Avg. growth/yr (5Y)8.0%
Balance & size
0.01×Debt / equity—
$239MMarket cap$81B
mixedGrowth qualityhealthy
HCA Healthcare leads: 4 to 6 metric wins.
Dash = not meaningfully computable, for example with negative equity.
Quality in detail
The quality score, broken down into the same factor families as on the stock page, 0 to 100 per family.
Tapdi Oksijen ASof which business quality 53 · market factors 49
HCA Healthcareof which business quality 66 · market factors 44
ProfitabilityMargins and returns on capital today
44
76
Quality GrowthAre margins and returns improving?
63
61
CashflowEarnings quality: real cash, not paper profit
40
62
Fin. StrengthBalance sheet, leverage, solvency risk
68
39
InvestmentDisciplined investing over empire-building
22
75
Low VolatilityCalm price path (market factor)
67
59
MomentumPrice trend over the last 3–12 months (market factor)
40
35
52W MomentumDistance to the 52-week high (market factor)
45
43
Net IssuanceBuybacks instead of dilution
82
100
What the models say
The median fair value (base case) per model family, each in the currency of its trading venue. Green = above the current price, red = below.
Tapdi Oksijen AS
DCF ModelsTRY 51.26
Earnings-BasedTRY 60.87
Dividend DiscountTRY 2.76
MultiplesTRY 32.18
Asset-BasedTRY 13.41
Growth DCFTRY 29.75
Economic ProfitTRY 23.12
Growth EarningsTRY 78.44
10 of 26 models see the stock below the current price.
HCA Healthcare
DCF Models$519
Earnings-Based$289
Dividend Discount$53.85
Multiples$612
Growth DCF$540
Economic Profit$419
Growth Earnings$478
6 of 23 models see the stock below the current price.
Scenario ranges
From our cautious bear case to the optimistic bull case. The white tick is the current price: left of fair value means room to run.
Tapdi Oksijen AS
Bear TRY 15.30Fair Value TRY 22.82Bull TRY 30.44
TRY 28.32 = current price (white tick)
HCA Healthcare
Bear $270Fair Value $555Bull $841
$403 = current price (white tick)
Compare two other stocks
Tap a field and type again, ticker or company name.
Ranked within their sector
Where each stock sits within its sector peer group. Band = middle 50% of peers, tick = median, dot = this stock.
Tapdi Oksijen AS · Energy
Quality score54 · above median
Fair value upside-19% · above median
HCA Healthcare · Health Care
Quality score62 · Top 25%
Fair value upside+38% · Top 25%
Bottom line
As of Aug 2, 2026, Fair Value Calculator sees HCA Healthcare as the more attractively valued of the two: Tapdi Oksijen AS trades at TRY 28.32 versus a fair value of TRY 22.82 (-19%), while HCA Healthcare trades at $403 versus $555 (+38%).
HCA Healthcare has the higher quality score (62/100).
See the full analysis →
More comparisons
Popular match-ups from the same sectors, all with fair value and quality score.
Free · Top-25 report
See the undervalued quality stocks every month
Just your email for the monthly Top-25 report of the most undervalued quality stocks, with fair value, quality and price target. Plus 14 days of Pro to try, no card.
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click. Not financial advice.
A model-based valuation snapshot from 21 models. Values change with price and fundamentals; the date shown above applies.
